Talking Ketamine Podcast

Talking Ketamine
  • 0.0 (0)
  • Mentale Gesundheit
  • Wöchentlich

Explore the cutting-edge science and therapeutic potential of ketamine. Talking Ketamine offers evidence-based discussions to demystify its role in mental health and beyond, providing informed insights into this powerful compound. Each episode explores a recent scientific study that explores an interesting aspect of ketamine treatment, ketamine therapy, and ketamine use in mental health. The podcast has covered topics ranging from ketamine and music to ketamine's surprising help in battling some cancers. Most of the papers covered are cutting edge science so you may not want to make medical decisions from them. But, each piece of evidence, good or bad, big or small, guides us to a better understanding of this miraculous medicine. If you are interested in ketamine research because you suffer from MDD or are having thoughts of suicide, please dial 988 or visit https://988lifeline.org in the US or go to https://findahelpline.com/ to find help in your location.

  1. Ketamine and Burnout

    vor 6 Tagen

    Ketamine and Burnout

    When standard self-care options fail and professional stress reaches a breaking point, can a clinical ketamine protocol act as a biological intervention to reverse burnout? In this episode of the Talking Ketamine podcast, we examine a pioneering 2026 retrospective analysis of 395 adults, titled "Burnout Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 395 Adults," by Swain et al. This study tracks the real-world impact of a telehealth-guided, at-home ketamine-assisted therapy program—conducted via the Mindbloom platform—to evaluate whether repairing neural pathways can pull exhausted professionals back from the brink. Occupational burnout is far more than just a stressful week at the office; it is a chronic syndrome recognized by the World Health Organization that degrades well-being across three distinct dimensions. It starts with emotional exhaustion, leaving individuals feeling like they are running on an empty battery, completely drained of life force. To protect itself from this severe depletion, the brain constructs a defensive firewall of cynicism, emotionally detaching and viewing work and colleagues as active threats. Finally, professionals experience a collapse of professional efficacy—a state akin to spinning wheels in thick mud, where immense effort is expended but results in zero sense of accomplishment or progress. While chronic stress causes neural pathways to wither under high cortisol levels, ketamine prompts a massive surge of glutamate, triggering synaptogenesis to rapidly repair these connections and silence the blaring alarms of the acute stress response. The clinical findings reveal a staged recovery process: while exhaustion and cynicism improve rapidly (nearly half of the total improvement occurs by the second session), rebuilding professional efficacy takes much longer, with only 26.3% of participants showing significant improvement. While a biological intervention can quickly recharge the battery and drop the firewall, rewriting the cognitive appraisal of one's capabilities requires real-world feedback and lived experiences of success. Furthermore, this episode addresses the study's critical limitations: because burnout heavily overlaps with clinical depression, it is difficult to isolate ketamine's direct effect from general mood improvement. Additionally, high dropout rates (only 24.1% of the initial cohort completed all assessments) and the statistical quirk of regression to the mean highlight the need for further controlled trials before characterizing at-home ketamine as a definitive cure for workplace burnout. Reference: Swain, J., Carter, D., Vando, L., & Reardon, I. (2026). Burnout symptom outcomes during at-home ketamine-assisted therapy: A real-world retrospective analysis of 395 adults. Research Square. https://doi.org/10.21203/rs.3.rs-10020276/v1

    20 Min.
  2. Navigating K-Land

    29. Juni

    Navigating K-Land

    Can a dissociative drug create the mental breathing room needed to break a decade-long cycle of severe methamphetamine addiction? In this episode of the Talking Ketamine podcast, we explore the groundbreaking KAPPA pilot trial detailed in the qualitative study, 'Navigating ‘k-land’: a qualitative exploration of participants’ experiences of ketamine-assisted psychotherapy for methamphetamine use disorder' by Fletcher et al. The study follows 14 individuals struggling with severe methamphetamine use disorder (MAUD)—many of whom had faced years of chronic treatment failure and deep societal stigma—as they undergo a novel clinical intervention combining subanesthetic ketamine infusions with cognitive behavioral therapy (CBT). For individuals with a history of chronic methamphetamine use, everyday life feels like being stuck on a broken treadmill with the incline and speed maxed out. Over time, chronic use hijacks the brain's reward center, building a rigid 'glutamate superhighway' that turns triggers into automatic, compulsive drug seeking. In this state, standard therapies bounce right off, like planting a seed in frozen, rock-hard winter soil. Ketamine acts as an NMDA receptor antagonist, temporarily placing a roadblock on this superhighway. This thaws the soil and acts as a remote control, allowing patients to hit a crucial 'pause button' to observe triggers without being consumed by cravings. It is a critical 'foot in the door' that dampens emotional volatility and provides transient 'psychological space.' However, this pause button is only temporary, and the wet concrete of the brain will eventually solidify again. This is why psychotherapy and integration are vital. By delivering cognitive behavioral therapy (CBT) within the 24 to 48 hours following a ketamine session—when a surge of BDNF acts like 'miracle grow' for the brain—patients can actively absorb the therapeutic tools and 'nail down' long-term behavioral changes. Ultimately, the KAPPA trial highlights that ketamine is not a magic wand, but a facilitative tool. While behavioral outcomes remain variable and dependent on ongoing commitment, this combined treatment offers a hopeful, dignified path forward for those seeking to reclaim agency over their lives. Reference: Fletcher, K., Ezard, N., Siefried, K. J., van der Helder, S., Freestone, J., Brett, J., May, R., Acheson, L., & Clifford, B. (2026). Navigating ‘k-land’: A qualitative exploration of participants’ experiences of ketamine-assisted psychotherapy for methamphetamine use disorder. Frontiers in Psychiatry, 17, Article 1873497. https://doi.org/10.3389/fpsyt.2026.1873497

    16 Min.
  3. Ketamine and Sleep

    19. Juni

    Ketamine and Sleep

    For years, the bone-deep exhaustion of treatment-resistant depression (TRD) was dismissed as a secondary symptom of a mood disorder. However, a landmark placebo-controlled clinical trial from the National Institutes of Health (NIH) has revealed a biological reality: depressed brains suffer from a corrupted sleep engine. Using a two-process model of sleep, the researchers focused on "Process S"—the homeostatic sleep drive that builds up chemical pressure (via adenosine) throughout the day. Under normal conditions, this pressure triggers "synaptic downscaling" during deep non-rapid eye movement (NREM) sleep, which behaves like clearing a computer's cache or turning down the background volume on waking connections. In TRD patients, the internal thermostat for this process is broken, leading to a severe deficit in slow-wave activity (SWA), particularly during the crucial first 90-minute cycle of the night (NREM1). This leaves patients waking up feeling like they ran a marathon in their sleep—analogous to a smartphone with corrupted battery software that only ever charges to 10% while background apps drain the system. The NIH study monitored 91 unmedicated TRD patients and 42 healthy volunteers in a specialized sleep lab using polysomnography. To ensure the validity of Process S, patients were kept awake all day playing board games to prevent them from "bleeding off" sleep pressure through daytime naps. The results were dramatic: a single IV infusion of ketamine (0.5 mg/kg) acted as a hard operating system reboot on the very first night. In patients who responded clinically to ketamine (defined by a 50% or greater drop in depression scores on the MADRS scale), sleep efficiency rose past 87%, total sleep time surpassed 400 minutes, and sleep latency dropped from 30 minutes to under 20. In contrast, healthy volunteers showed no changes due to a "ceiling effect" (their systems were already running optimally), while non-responders' sleep architecture remained broken. Unlike traditional sleep aids that act as chemical off-switches creating "junk sleep" while suppressing deep waves, ketamine functions as a biological system administrator that clears the cache and executes the brain's natural restorative maintenance. However, the study also revealed a crucial limitation: the sleep-reboot effect diminished with age, especially in older non-responders. Mechanistically, ketamine triggers a glutamate burst that releases brain-derived neurotrophic factor (BDNF). While pop science describes BDNF as "fertilizer for the brain," it is more akin to an aggressive biological construction crew deploying jackhammers to break down rigid, depressed neural pathways and build new dendritic branches. To succeed, this crew needs "plasticity reserve"—the concrete and steel raw materials that naturally decline with age and decades of chronic depression. When the brain has been immobilized in a cast of depressive rigidity for decades, a single infusion is not enough. Rebuilding this reserve requires a sustained protocol resembling physical therapy, such as stacked dosing and behavioral therapies. Ultimately, this breakthrough suggests that consumer sleep wearables could soon replace subjective psychiatric questionnaires by tracking overnight slow-wave recovery, providing doctors with objective biological data confirming if a patient's physical hardware is actively healing by breakfast. Reference: Hejazi, N., Kheirkhah, M., Riedner, B., Yuan, Q., Chholak, R., Momenan, R., Jones, G., Goldman, D., & Zarate, C. A., Jr. (2026). Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression. Neuropsychopharmacology. Advance online publication. https://doi.org/10.1038/s41386-026-02465-4

    21 Min.
  4. Ketamine for Prolonged Grief

    12. Juni

    Ketamine for Prolonged Grief

    For the estimated seven to ten percent of bereaved adults struggling with Prolonged Grief Disorder (PGD), mourning isn’t a slow march forward; it is a state of total paralysis. While typical grief allows the internal clock to keep ticking as the world spins, PGD jams the gears of recovery, trapping individuals in a closed loop of loss-oriented rumination and profound identity disruption. Standard psychiatric treatments like SSRIs frequently fail because PGD is not merely depression, and specialized, multi-session psychotherapies remain difficult for most people to access. This episode dives into a retrospective analysis of 503 adults who underwent Mindbloom's guided, at-home telehealth ketamine therapy. By acting as an NMDA receptor antagonist, ketamine decreases functional connectivity within the hyperactive default mode network (DMN)—the brain's self-referencing storytelling engine that holds onto stubborn expectations, or "high-level neural priors." Using the analogy of deeply rutted dirt roads, the constant agonizing loop of grief digs tracks so deep that the mind's tires cannot steer out of them. Ketamine essentially smooths out the dirt, filling these ruts and providing the cognitive flexibility needed for the tires to find traction. This biological window aligns with the dual process model of bereavement, allowing patients to shift from paralyzing loss to active life restoration, and ultimately reprogram their internal GPS. The clinical findings are striking: among the 121 participants who completed the six-session protocol, grief scores declined consistently, leading to a 31% average reduction in symptoms and a 76% clinical response rate. Crucially, the single largest improvement—standing at nearly 36%—occurred not in general sadness, but in identity and role confusion. While the study faces limitations like high attrition (completer bias) and the lack of a placebo control, worst-case sensitivity analysis still confirms a robust diagnostic remission rate of 18-19%. These results suggest that healing from profound loss is not a passive waiting game, but an active process of rebuilding who we are. Reference: Carter, D., Reardon, I., Swain, J., & Vando, L. (2026). Prolonged grief symptom outcomes during at-home ketamine-assisted therapy: A real-world retrospective analysis of 503 adults. Research Square. https://doi.org/10.21203/rs.3.rs-9839240/v1

    20 Min.
  5. Couples Therapy on Ketamine

    5. Juni

    Couples Therapy on Ketamine

    For many couples, traditional talk therapy can feel like an endless loop, failing to break through entrenched patterns of distress. The stark reality? Up to a third of couples find conventional therapy ineffective, often relapsing into old arguments because logic crumbles when the nervous system is trapped in a defensive state. When our amygdala, the brain's fear processing center, perceives a partner as a threat, our survival instincts take over, shutting down the very connection we crave. Enter ketamine-assisted psychotherapy (KAP) in the relational space—a "benevolent disruptor" that biochemically dampens the amygdala, reducing fear and softening the sharp edges of human interaction. This episode unpacks a groundbreaking qualitative study profiling nine therapists who are integrating ketamine into their work with dyads, revealing diverse, highly structured approaches tailored to specific relational challenges. Whether it's a psycholytic (medium) dose to facilitate unarmored communication in Imago Relationship Therapy, a psychedelic (macro) dose to provide radical perspective shifts in Integrative Behavioral Couple Therapy, or even staggered dosing in Emotionally Focused Couple Therapy to choreograph vulnerability and receptivity, ketamine acts as a catalyst for deeply meaningful encounters. For some, the Internal Family Systems (IFS) approach even involves only one partner taking a psychedelic dose, creating a "Golden Hour" of pure, undefended self-expression that can trigger "contagious empathy" in the sober partner. Crucially, the medicine is not a magic cure. It's a temporary window of opportunity. The lasting work happens in the meticulous preparation—where couples map out their conflict cycles and set clear intentions—and the essential integration phase, where abstract insights are transformed into practical, daily habits. While the field is nascent and requires further rigorous research, these pioneering therapists are exploring how ketamine can foster radical vulnerability and help couples redefine relationship work, moving from relentless fighting to simply learning how to put the armor down and access the deep connection that's already there. Reference: Avruch, D. O. (2026). Approaches to ketamine-assisted couple therapy. Frontiers in Psychology, 17, Article 1843151. https://doi.org/10.3389/fpsyg.2026.1843151

    24 Min.
  6. Ketamine and Buprenorphine

    30. Mai

    Ketamine and Buprenorphine

    Ketamine offers rapid relief from severe depression and suicidal ideation, but its effects are often fleeting, creating a "fade" that leaves patients vulnerable. This Stanford study, published in the *American Journal of Psychiatry* (2026), tackles this challenge by exploring a novel pharmacological strategy: using low-dose buprenorphine to extend ketamine's benefits. Researchers discovered that ketamine's magic might rely on the brain's mu-opioid receptor pathways, not just the glutamate system. Buprenorphine, a partial mu-opioid agonist, gently stimulates these pathways, acting like a "trellis" to support new neural connections formed by ketamine. This approach, tested on outpatients with severe depression and suicidal ideation, showed remarkable results. Patients receiving buprenorphine maintained a significant reduction in suicidal thoughts, while those on a placebo experienced a return of ideation. Intriguingly, buprenorphine specifically targeted suicidal ideation without significantly impacting overall depression. This suggests that these conditions may operate on distinct neurobiological circuits, challenging the conventional view that suicidal ideation is simply an extreme symptom of depression. This study provides a potentially scalable and safe therapeutic option, offering a new key to turn off the switch for patients in desperate need. Reference: Tucciarone, J. M., Bandeira, I. D., Blasey, C., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., Bernert, R., DeBattista, C., Truong, H., Rodriguez, C. I., Heifets, B. D., & Schatzberg, A. F. (2026). Low-dose buprenorphine following ketamine treatment for suicidal ideation in major depressive disorder: A randomized, double-blind, placebo-controlled trial. *American Journal of Psychiatry*, *XX*(XX), 1–11. https://doi.org/10.1176/appi.ajp.20250840

    22 Min.
  7. Ketamine Therapeutic Guidelines

    22. Mai

    Ketamine Therapeutic Guidelines

    Ketamine therapy, a beacon of hope for treatment-resistant depression, has been gaining traction, but its off-label use has raised concerns about standardization and safety. Imagine a powerful dissociative anesthetic, originally intended for battlefield use, being administered in strip mall clinics without proper monitoring or trained psychiatric support! The risk? A destabilized patient leaving traumatized instead of healed. Enter the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3), armed with a rigorous, interdisciplinary approach using the Delphi method. This isn't your typical boardroom vote; it's an anonymous, iterative process designed to eliminate bias and ego, ensuring that guidelines reflect true expert consensus. With insights from psychiatrists, anesthesiologists, ER physicians, and psychotherapists, the new guidelines address crucial aspects like comprehensive patient evaluations, dose titration, and monitoring requirements. These guidelines aren't just about individual safety; they're a step toward standardizing the industry, paving the way for insurance coverage and broader access. But will these new rules squeeze out clinics prioritizing profit over patient well-being? And what does this mean for the future of other emerging mental health therapies waiting in the wings? Reference: Mathai, D. S., Cluck, M., Aslam, A. M., Amato, E., Azam, A., Banov, M., Barrett, K. A., Bonnett, C. J., Feifel, D., Grundmann, N., Ko, H. S., McShane, R., Prashad, S., Santini, T., Stewart, L. H., Sullivan, P., Wolfsohn, S. D., Robinson, J. O., McGuire, A. L., & McInnes, L. A. (2026). Interdisciplinary, delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3). Journal of Affective Disorders, 121970. https://doi.org/10.1016/j.jad.2026.121970

    20 Min.
  8. Ketamine's Hidden Interactions: A Transplant Patient's Tale

    14. Mai

    Ketamine's Hidden Interactions: A Transplant Patient's Tale

    This episode dives into a 2026 case report revealing a surprising drug interaction: ketamine, used for pain management, induced the liver to accelerate the breakdown of critical immunosuppressant medications in a heart transplant recipient. Transplant patients rely on a delicate balance, where drugs like tacrolimus and sirolimus prevent organ rejection. However, these drugs are metabolized by specific liver enzymes (CYP3A4), making them vulnerable to interactions. In this case, a patient receiving ketamine for post-surgical pain experienced a dramatic drop in immunosuppressant levels, placing his transplanted heart at risk. Doctors responded by drastically increasing the doses, but the drug concentrations barely budged. The ketamine was essentially "teaching" the liver to clear the drugs faster, a phenomenon known as enzyme induction. The peak effect occurred a week after ketamine was started, followed by a slow recovery over three weeks. The episode emphasizes the importance of vigilant monitoring when ketamine is used in patients on narrow therapeutic range medications, and that monitoring should continue for three weeks after ketamine is discontinued to catch any potential rebound effects. Reference: Stojanova, J., Murnion, B., Burrows, F., Carlos, L., Mizuno, T., Nadai, T., Helsby, N., Muthiah, K., & Day, R. (2026). Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, *46*(e70150). https://doi.org/10.1002/phar.70150

    8 Min.
Alle anzeigen (70)

Info

Explore the cutting-edge science and therapeutic potential of ketamine. Talking Ketamine offers evidence-based discussions to demystify its role in mental health and beyond, providing informed insights into this powerful compound. Each episode explores a recent scientific study that explores an interesting aspect of ketamine treatment, ketamine therapy, and ketamine use in mental health. The podcast has covered topics ranging from ketamine and music to ketamine's surprising help in battling some cancers. Most of the papers covered are cutting edge science so you may not want to make medical decisions from them. But, each piece of evidence, good or bad, big or small, guides us to a better understanding of this miraculous medicine. If you are interested in ketamine research because you suffer from MDD or are having thoughts of suicide, please dial 988 or visit https://988lifeline.org in the US or go to https://findahelpline.com/ to find help in your location.

Informationen

  • Erstellt von
    Talking Ketamine
  • Jahre aktiv
    2024 - 2026
  • Folgen
    70
  • Bewertung
    Unbedenklich
  • Copyright
    © 2026 Talking Ketamine
  • Sendungswebsite
    Talking Ketamine Podcast

Das gefällt dir vielleicht auch